2486 related articles for article (PubMed ID: 12875604)
41. [Neoadjuvant treatment of early breast cancer: new drugs contribution].
Giacchetti S; Cuvier C; Hocini H; Bourstyn E; de Roquancourt A; Espié M
Bull Cancer; 2004 Dec; 91 Suppl 4():S232-8. PubMed ID: 15899614
[TBL] [Abstract][Full Text] [Related]
42. Rationale and use of epirubicin-based therapy in the adjuvant setting.
Mouridsen HT
Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S34-40. PubMed ID: 11970748
[TBL] [Abstract][Full Text] [Related]
43. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.
Biganzoli L; Aapro M; Loibl S; Wildiers H; Brain E
Cancer Treat Rev; 2016 Feb; 43():19-26. PubMed ID: 26827689
[TBL] [Abstract][Full Text] [Related]
44. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
45. Recent progress in the clinical development of docetaxel (Taxotere).
Hortobagyi GN
Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
[TBL] [Abstract][Full Text] [Related]
46. Interaction between Herceptin and taxanes.
Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
47. The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer.
Gogas H; Fountzilas G
Ann Oncol; 2003 May; 14(5):667-74. PubMed ID: 12702519
[No Abstract] [Full Text] [Related]
48. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
Valero V; Perez E; Dieras V
Semin Oncol; 2001 Aug; 28(4 Suppl 12):15-23. PubMed ID: 11552226
[TBL] [Abstract][Full Text] [Related]
49. Putting taxanes to work in operable breast cancer: a search for selective indications from empirical studies.
Gianni L; Capri G; Valagussa P; Bonadonna G
Recent Results Cancer Res; 1998; 152():314-22. PubMed ID: 9928568
[TBL] [Abstract][Full Text] [Related]
50. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
51. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
52. Prospects with docetaxel in the treatment of patients with breast cancer.
Marty M; Extra JM; Cottu PH; Espié M
Eur J Cancer; 1997 Aug; 33 Suppl 7():S26-9. PubMed ID: 9486101
[TBL] [Abstract][Full Text] [Related]
53. Taxanes in adjuvant breast cancer setting: which standard in Europe?
Campone M; Fumoleau P; Bourbouloux E; Kerbrat P; Roché H
Crit Rev Oncol Hematol; 2005 Sep; 55(3):167-75. PubMed ID: 16039867
[TBL] [Abstract][Full Text] [Related]
54. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
55. The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
Nabholtz JM; Riva A
Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S7-14. PubMed ID: 11970739
[TBL] [Abstract][Full Text] [Related]
56. Current status of taxanes as adjuvant therapy for early-stage breast cancer.
Wolff AC
Int J Fertil Womens Med; 2005; 50(5 Pt 1):227-9. PubMed ID: 16468473
[TBL] [Abstract][Full Text] [Related]
57. Docetaxel: a taxoid for the treatment of metastatic breast cancer.
Tankanow RM
Am J Health Syst Pharm; 1998 Sep; 55(17):1777-91. PubMed ID: 9775340
[TBL] [Abstract][Full Text] [Related]
58. Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer.
Gradishar WJ
Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S31-5. PubMed ID: 11970742
[TBL] [Abstract][Full Text] [Related]
59. Taxanes in the treatment of breast cancer: a prodigy comes of age.
Miller KD; Sledge GW
Cancer Invest; 1999; 17(2):121-36. PubMed ID: 10071597
[TBL] [Abstract][Full Text] [Related]
60. Taxane/anthracycline combinations: setting a new standard in breast cancer?
Nabholtz JM; Riva A
Oncologist; 2001; 6 Suppl 3():5-12. PubMed ID: 11346678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
